M
Martin C. Müller
Researcher at Heidelberg University
Publications - 179
Citations - 14792
Martin C. Müller is an academic researcher from Heidelberg University. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 54, co-authored 178 publications receiving 13711 citations. Previous affiliations of Martin C. Müller include University Hospital Heidelberg & Medical University of Graz.
Papers
More filters
Journal ArticleDOI
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,François Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Charles A. Schiffer,Richard T. Silver,Bengt Simonsson,Juan Luis Steegmann,John M. Goldman,Rüdiger Hehlmann +31 more
TL;DR: Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
Journal ArticleDOI
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Andreas Hochhaus,Sebastian Kreil,Amie S. Corbin,P La Rosée,P La Rosée,Martin C. Müller,T. Lahaye,Benjamin Hanfstein,Claudia Schoch,Nicholas C.P. Cross,Ute Berger,Harald Gschaidmeier,Brian J. Druker,Ruediger Hehlmann +13 more
TL;DR: Although the heterogeneous development of imatinib resistance is challenging, the fact that BCR-ABL is active in many resistant patients suggests that the chimeric oncoprotein remains a good therapeutic target.
Journal ArticleDOI
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Jorge E. Cortes,Dong-Kee Kim,Javier Pinilla-Ibarz,P. le Coutre,Ronald Paquette,Charles Chuah,F. E. Nicolini,Jane F. Apperley,Hanna Jean Khoury,Moshe Talpaz,John F. DiPersio,Daniel J. DeAngelo,Elisabetta Abruzzese,Delphine Rea,Michele Baccarani,Martin C. Müller,Carlo Gambacorti-Passerini,Stephane Wong,Stephanie Lustgarten,Victor M. Rivera,Timothy P. Clackson,Christopher D. Turner,Frank G. Haluska,François Guilhot,Michael W. Deininger,Andreas Hochhaus,Timothy P. Hughes,J. M. Goldman,Neil P. Shah,Hagop M. Kantarjian +29 more
TL;DR: Ponatinib had significant antileukemic activity across categories of disease stage and mutation status and were durable; the estimated rate of a sustained major cytogenetic response of at least 12 months was 91%.
Journal ArticleDOI
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
Andreas Hochhaus,Stephen G. O'Brien,François Guilhot,B. J. Druker,Susan Branford,Letizia Foroni,JohnM. Goldman,Martin C. Müller,Jerald P. Radich,Marc Rudoltz,Manisha Mone,Insa Gathmann,Timothy P. Hughes,Richard A. Larson +13 more
TL;DR: During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC), and the toxicity profile was unchanged.
Journal ArticleDOI
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus,Hagop M. Kantarjian,Michele Baccarani,Jeffrey H. Lipton,Jane F. Apperley,Brian J. Druker,Thierry Facon,Stuart L. Goldberg,Francisco Cervantes,Dietger Niederwieser,Richard T. Silver,Richard Stone,Timothy P. Hughes,Martin C. Müller,Rana Ezzeddine,A. Countouriotis,Neil P. Shah +16 more
TL;DR: Dasatinib induces notable responses in imatinib-resistant or -intolerant CML-CP, is well tolerated, and represents a promising therapeutic option for these patients.